July 23, 2024—BioPorto Diagnostics will unveil its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago. The post BioPorto to unveil FDA-cleared NGAL test at ADLM first appeared on CAP TODAY ..read more

July 2024 Q. Insulin assays traditionally have been used to work up hypoglycemia, but we are noticing more and more requests for insulin and C-peptide testing. Is there a reason for this shift? Read answer. Q. How should a lot-to-lot formalin comparison be done? Read answer. The post Q&A column first appeared on CAP TODAY ..read more

July 2024—The CAP, Association for Molecular Pathology, and Society for Immunotherapy of Cancer released in June their recommendations for tumor mutational burden assay validation and reporting. The joint publication summarizes the existing knowledge and challenges related to TMB testing. The authors make 13 recommendations related to testing, reporting, and publications on TMB assays. The post Put It on the Board first appeared on CAP TODAY ..read more

July 2024—A Mayo Clinic project is “democratizing artificial intelligence,” its leaders say, by enabling pathologists with varying levels of AI expertise—most of whom had never before participated in an AI project—to create and implement algorithms. The post Mayo pathologists create and test their own AI algorithms first appeared on CAP TODAY ..read more

July 2024—Earlier this year the laboratory at King Salman Armed Forces Hospital joined more than 120 other Saudi labs in achieving CAP accreditation. And it did so with a boost from LEAP. The 665-bed hospital needed to adopt standards for nearly all technical specialties and comply with more than 1,000 CAP requirements. The post Using LEAP, Saudi laboratory attains accreditation first appeared on CAP TODAY ..read more

July 2024—The term value-based care is spoken of often, but what part do laboratories play in it and how can they be paid for it? What is Medicare 2030, and what does it mean for laboratories? How can AI be used to practice the medicine of tomorrow? Myra Wilkerson, MD, in speaking in May at the Pathology Informatics Summit, answered these and other questions. She is chair of the Department of Laboratory Medicine and of the Diagnostic Medicine Institute at Geisinger Health in Danville, Pa. She is a founding member of the Project Santa Fe Foundation, for which she serves on its board and as trea ..read more

July 2024—The University of Maryland Medical Center is one of many sites using low titer O whole blood in trauma cases. As of May, 720 patients at UMMC had received whole blood, and that number of patients treated since the program’s start in 2021 speaks for itself, says Bryon P. Jackson, MD, MHA, Midtown Campus laboratory director and director of blood management and associate director of transfusion medicine services. The post At U of Maryland, low titer O whole blood use in trauma first appeared on CAP TODAY ..read more

July 2024—Remote sign-out has become a major issue for pathologists, spurred in large part by the COVID-19 pandemic and the CAP’s advocacy efforts that led to our ability to sign out cases from other locations. The Centers for Medicare and Medicaid Services has allowed remote sign-out to continue long after the public health emergency was declared over and is considering making this a permanent rule. I recognize how popular remote sign-out has become and have enjoyed many of its advantages in my own practice. However, I also see a few possible unintended consequences that I think are very impo ..read more

July 2024—People with sickle cell disease may undergo treatment with the medication voxelotor, which can increase hemoglobin levels and help reduce hemolysis. A clinician treating a sickle cell disease patient with voxelotor may want to know the whole blood concentration of the drug to better monitor the patient’s treatment response, inform therapy, or confirm the patient is complying with the directions for use of the drug. Voxelotor binds to the alpha subunit of hemoglobin and results in the hemoglobin molecule being more likely to stay in the oxygenated conformation. In vivo concentrations ..read more

July 2024—The 2022 International Society of Urological Pathology consensus conference on urinary bladder cancer working group two was tasked with providing evidence-based proposals on applying grading to noninvasive urothelial carcinoma with mixed grades; invasive urothelial carcinoma, including subtypes and divergent differentiations; and pure non-urothelial carcinomas. Studies suggested that predominantly low-grade noninvasive papillary urothelial carcinoma with focal high-grade component has an intermediate outcome between low- and high-grade tumors. However, no consensus was reached on how ..read more